BIIB
AR$13,075.00
▼-0.19%
Stock
Biogen Inc.
Official Company Name: Biogen Inc.
Stock Symbol: BIIB
Stock Market: Buenos Aires Stock Exchange - BCBA
Currency: Argentine peso - ARS
BIIB Stock Price - 1 Year Price Evolution & Moving Averages
1 Year Return
▼-32.00%
Daily closing prices, with moving averages and volumes - Argentine peso (ARS)
Moving averages:
- — EMA20
- — SMA50
- — SMA200
Biogen Inc. Categories
United States
languages
Healthcare
languages
Drug Manufacturers—General
Healthcare
Drug Manufacturers—General
Company Description
Biogen Inc. is a biotechnology company specialized in the treatment of neurological diseases. It researches, develops, and markets therapies for a range of diseases including Alzheimer’s disease, hemophilia, multiple sclerosis, spinal muscular atrophy, plaque psoriasis, leukemia, rheumatoid arthritis, lymphoma, neurocognitive disorders, and pain.
BIIB Stock Data
| Open | AR$13,025.00 |
| High | AR$13,150.00 |
| Low | AR$12,950.00 |
| Close | AR$13,075.00 |
| Volume | 241 |
| Previous Close | AR$13,100.00 |
| 1-Day Change | -25.00 |
| 1-Year Change | -6152.00 |
| Average Daily Volume | 490 |
| 52-Week High | AR$25,700.00 |
| 52-Week Low | AR$12,700.00 |
Disclaimer
All information and data available on Disfold is NOT FINANCIAL ADVICE. Invest at your own risk!
Past performance is not a guarantee of future performance. Patterns tend to repeat themselves, but they don't necessarily have to.
Successful backtests on past data do not guarantee the future success of the strategy backtested, especially as backtest overfitting may occur: when the price of a stock may fit particularly well a given trading strategy over a given period, but not necessarily outside of that period. Besides, backtests do not account for exact market conditions and may yield significantly different results in real trading practice (fees, slippage...).
Furthermore, even though Disfold strives to provide the best and most accurate data, errors can occur in Disfold's systems, or in our data providers' systems.
Please conduct your own due diligence to verify insights.